Invivoscribe Marketing, Author at Invivoscribe

About Invivoscribe Marketing

This author has not yet filled in any details.
So far Invivoscribe Marketing has created 142 blog entries.

Unlocking the Potential of NGS Clonality and MRD Testing: From Research to High-Throughput Environments – Part 02

Invivoscribe Marketing2024-07-16T15:02:54-07:00June 25th, 2024|2024 Videos, Featured Videos, Videos|

Clonality and Measurable Residual Disease (MRD) Testing on the Illumina NextSeq Sequencers

Invivoscribe Marketing2024-06-21T12:55:12-07:00June 21st, 2024|2024 Publications, Featured Publications, Publications|

Study Suggests Critical Link Between Residual FLT3-ITD Mutations in Remission and Post-Transplant Outcomes in AML

Invivoscribe Marketing2024-05-07T17:44:56-07:00May 8th, 2024|2024 Press Releases, Press Releases|

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Invivoscribe Marketing2024-05-02T11:47:00-07:00May 2nd, 2024|2024 Publications, Featured Publications, Publications|

Level Up Your MRD Testing: Leveraging Standardized & Sensitive AML Assessments

Invivoscribe Marketing2024-04-01T16:59:27-07:00March 20th, 2024|2024 Videos, Featured Videos, Videos|

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Invivoscribe Marketing2024-03-26T13:55:01-07:00March 20th, 2024|2024 Publications, Featured Publications, Publications|

Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal residual disease detection in Chinese patients with multiple myeloma

Invivoscribe Marketing2024-03-26T13:50:51-07:00March 19th, 2024|2024 Publications, Featured Publications, Publications|

Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms

Invivoscribe Marketing2024-03-03T11:41:21-08:00March 1st, 2024|2024 Publications, Featured Publications, Publications|

ASH 2024

Invivoscribe Marketing2024-02-29T09:31:20-08:00December 7th, 2023|Conferences|

JSLM Annual Meeting 2024

Invivoscribe Marketing2024-02-16T16:13:53-08:00November 28th, 2023|Conferences|

AMP 2024

Invivoscribe Marketing2024-02-15T15:50:31-08:00November 19th, 2023|Conferences|

The Evolving Role of NGS and Measurable Residual Disease in CLL/SLL and AML

Invivoscribe Marketing2024-02-08T15:09:04-08:00November 16th, 2023|2023 Videos, Featured Videos, Videos|

JSH 2024

Invivoscribe Marketing2024-02-15T16:40:10-08:00October 11th, 2023|Conferences|

ICCS 2024

Invivoscribe Marketing2024-02-16T16:08:13-08:00October 4th, 2023|Conferences|

EA4HP-SH 2024

Invivoscribe Marketing2024-02-16T16:12:53-08:00September 21st, 2023|Conferences|

CMACSH Chinese Society of Hematology Conference 2024

Invivoscribe Marketing2024-02-16T16:06:24-08:00September 20th, 2023|Conferences|

CGC Annual Meeting 2024

Invivoscribe Marketing2024-02-16T16:04:32-08:00August 4th, 2023|Conferences|

Invivoscribe Announces FDA Approval of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with FLT3-ITD Positive AML for Treatment with VANFLYTA

Invivoscribe Marketing2023-07-20T17:27:41-07:00July 21st, 2023|2023 Press Releases, Press Releases|

AMP Europe 2024

Invivoscribe Marketing2024-02-16T15:55:20-08:00June 24th, 2023|Conferences|

MRD Applications and Analysis

Invivoscribe Marketing2023-07-11T18:20:48-07:00June 20th, 2023|2023 Videos, Featured Videos, Videos|

EHA 2024

Invivoscribe Marketing2024-02-29T09:27:59-08:00June 13th, 2023|Conferences|

Invivoscribe Partners with Complete Genomics to Develop and Commercialize Biomarker Tests for Oncology and Cancer Research

Invivoscribe Marketing2023-06-05T12:37:16-07:00June 2nd, 2023|2023 Press Releases, Press Releases|

NGS Assessment of SHM in CLL/SLL: A Practical Comparison of Platforms and Primers

Invivoscribe Marketing2023-06-06T16:30:52-07:00May 31st, 2023|2023 Videos, Featured Videos, Videos|

ASCO 2024

Invivoscribe Marketing2024-02-16T15:59:13-08:00May 31st, 2023|Conferences|

Invivoscribe Announces Updated Reimbursement for the LeukoStrat CDx FLT3 Mutation Assay to Select Newly Diagnosed FLT3-ITD Positive AML Patients Eligible for VANFLYTA in Japan

Invivoscribe Marketing2023-05-25T17:09:22-07:00May 25th, 2023|2023 Press Releases, Press Releases|